Viewray Inc to Post FY2019 Earnings of ($1.09) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:VRAY)

Share on StockTwits

Viewray Inc (NASDAQ:VRAY) – Stock analysts at Cantor Fitzgerald lifted their FY2019 earnings per share estimates for shares of Viewray in a research report issued to clients and investors on Thursday, December 5th. Cantor Fitzgerald analyst C. Bijou now forecasts that the company will post earnings per share of ($1.09) for the year, up from their previous estimate of ($1.12). Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Viewray’s FY2020 earnings at ($0.62) EPS.

Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. Viewray had a negative net margin of 110.61% and a negative return on equity of 75.41%. The business had revenue of $20.90 million during the quarter, compared to analyst estimates of $20.66 million. During the same period in the prior year, the business earned ($0.39) EPS. The company’s revenue for the quarter was up 18.1% on a year-over-year basis.

Several other research analysts have also issued reports on VRAY. ValuEngine upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. Zacks Investment Research lowered shares of Viewray from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 16th. Piper Jaffray Companies set a $6.00 price target on shares of Viewray and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Oppenheimer started coverage on shares of Viewray in a research note on Tuesday, October 22nd. They issued an “outperform” rating and a $7.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $8.00 price target on shares of Viewray in a research note on Tuesday, December 3rd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $6.10.

Shares of NASDAQ VRAY opened at $4.20 on Monday. The company has a current ratio of 3.70, a quick ratio of 2.58 and a debt-to-equity ratio of 0.62. The firm has a fifty day simple moving average of $3.04 and a two-hundred day simple moving average of $5.39. The firm has a market capitalization of $410.07 million, a PE ratio of -4.29 and a beta of 1.09. Viewray has a 12 month low of $2.12 and a 12 month high of $9.76.

Several institutional investors have recently modified their holdings of the stock. Park West Asset Management LLC increased its stake in Viewray by 87.3% during the 2nd quarter. Park West Asset Management LLC now owns 7,615,325 shares of the company’s stock valued at $67,091,000 after purchasing an additional 3,549,255 shares in the last quarter. Perceptive Advisors LLC increased its stake in Viewray by 13.5% during the 2nd quarter. Perceptive Advisors LLC now owns 5,455,243 shares of the company’s stock valued at $48,061,000 after purchasing an additional 649,593 shares in the last quarter. BlackRock Inc. increased its stake in Viewray by 1.5% during the 2nd quarter. BlackRock Inc. now owns 4,894,543 shares of the company’s stock valued at $43,121,000 after purchasing an additional 72,529 shares in the last quarter. Vanguard Group Inc. increased its stake in Viewray by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,673,074 shares of the company’s stock valued at $32,359,000 after purchasing an additional 75,466 shares in the last quarter. Finally, Bamco Inc. NY increased its stake in Viewray by 18.3% during the 2nd quarter. Bamco Inc. NY now owns 1,875,809 shares of the company’s stock valued at $16,526,000 after purchasing an additional 290,000 shares in the last quarter.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Recommended Story: The components of the Stochastic Momentum Index

Earnings History and Estimates for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.